Abstract-Aortic stiffness and chronic kidney disease are closely linked by shared risk factors and associated increased cardiovascular mortality. At lower levels of renal function, aortic stiffness is independently associated with glomerular filtration rate. However, the longitudinal impact of aortic stiffness on renal function has not been reported previously. A cohort of 133 patients with chronic kidney disease stages 3 and 4 (estimated glomerular filtration rate: 15 to 59 mL/min per 1.73 m 2 ) underwent prospective measurement of arterial stiffness parameters and monitoring of renal function. Aortic pulse wave velocity measurement was performed in 120 patients. The mean age was 69Ϯ12 years (meanϮSD; 103 men, 30 women, and 23.3% diabetic). Mean systolic blood pressure was 155Ϯ21 mm Hg, and mean diastolic blood pressure was 83Ϯ11 mm Hg. The mean Modification of Diet in Renal Disease estimated glomerular filtration rate was 32Ϯ11 mL/min per 1.73 m 2 . Change in renal function was measured using reciprocal creatinine plots and the dichotomous combined end point of Ն25% decline in renal function or start of renal replacement therapy. After stepwise multivariate analysis, aortic pulse wave velocity was independently associated with gradient of reciprocal creatinine plot (rϭ0.46; Pϭ0.014). In multivariate analysis of the end point of Ն25% decline in renal function or start of renal replacement therapy, independent predictors were aortic pulse wave velocity (rϭ0.48; Pϭ0.002), systolic blood pressure (rϭ0.17; Pϭ0.039), and urine protein:creatinine ratio (rϭ0.20; Pϭ0.021). We, therefore, conclude that aortic stiffening is independently associated with rate of change in renal function in patients with chronic kidney disease stages 3 and 4. (Hypertension. 2010;55:00-00.) Key Words: aorta Ⅲ pulse pressure Ⅲ microvessels Ⅲ kidney Ⅲ creatinine Ⅲ pulse pressure Ⅲ renal insufficiency C hronic kidney disease (CKD) is a common condition, affecting 10% to 13% of the population of the United States, 1 associated with a dramatically increased cardiovascular (CV) mortality, which increases with severity of renal impairment. This excess CV risk is in part attributed to an increase of traditional risk factors among people with CKD 2 but may also relate to the complex metabolic and vascular changes of CKD, including arterial stiffening. Aortic stiffness increases progressively as renal function declines 3 and has been independently associated with CV mortality in patients with renal failure. 4, 5 Although much research has investigated the role of aortic stiffening in the causation of CV disease in patients with CKD, less attention has been paid to its potential etiologic role in the causation and progression of renal impairment. Aortic stiffening causes increased systolic blood pressure (BP; SBP) and widened pulse pressure (PP), both factors associated in longitudinal studies with increased rate of decline of renal function. 6, 7 In addition, aortic stiffening results in loss of the dampening of ventricular ejection and could lead to increased transmission of these pressure changes to organ microvasculature. 8 The renal microcirculation may be particularly affected because the low resistance provided by the renal afferent arterioles means that the glomerular capillaries are exposed to potentially damaging pulsatile pressures, which may result in a permanent reduction in glomerular filtration rate (GFR). 9 We, therefore, hypothesized that increased aortic stiffness would lead to more rapid decline in renal function independent of the impact of known risk factors for progression, including BP. We chose to test this hypothesis within the ACADEMIC (Arterial Compliance and Oxidant Stress as predictors of loss of renal function, morbidity and mortality in Chronic Kidney Disease [CKD] Study) cohort, a study of the progression of arterial stiffness and renal function in a cohort of patients with CKD stages 3 and 4. To our knowledge, this is the first study to examine the longitudinal relationship between change in renal function and the gold standard marker of aortic stiffness, aortic pulse wave velocity (PWV). 10
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Methods

Population
Patients were enrolled in a prospective study of vascular stiffness and CV risk in patients with CKD stages 3 and 4. They were predomi-nantly recruited from outpatients attending nephrology clinics at Brighton and Sussex University Hospitals National Health Service Trust from March 2006 to January 2008. Exclusion criteria included previous diagnosis of left ventricular failure, aortic stenosis with transvalvular gradient Ͼ30 mm Hg, and atrial fibrillation with uncontrolled ventricular response. All of the participants were treated with the aim of achieving United Kingdom Renal Association targets for management of BP in CKD 11 : a target BP of 130/ 80 mm Hg for patients with urine protein:creatinine ratio (uPCR) Ͻ100 mg/mmol and 125/75 mm Hg for those with uPCR Ͼ100 mg/mmol. The choice of antihypertensive medication was at the discretion of the patient's clinician but followed British Hypertension Society guidelines. 12 All of the participants were outpatients and stable on their antihypertensive regime at the time of the study. A full history of renal disease, CV disease, and other risk factors was obtained.
The study was approved by the West Sussex Research Ethics Committee, and patients gave written informed consent. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.
Clinical Measurements
Measurements were conducted in a quiet, temperature-controlled room by the same 2 trained research staff (a nurse and a doctor) throughout the study. Oscillometric BP was measured twice using an appropriate cuff size with the patient supine after 5 and 10 minutes of rest (Omron 705 CP). The mean of the 2 recordings of SBP and diastolic BP (DBP) was recorded. Mean BP (MBP) was calculated using the following equation: MBPϭ(SBPϪDBP)/3ϩDBP.
Aortic stiffness was measured using Complior (Artech Medical) 13 according to best-practice guidelines. 10 Pulse waves were recorded transcutaneously at the right femoral and common carotid arteries simultaneously, and the distance between the 2 recording sites was measured. Complior software calculated the time interval between the recorded waves, and PWV was obtained using the following equation: PWVϭdistance/time. 13 
Laboratory Measurements
Biochemical and hematologic parameters were measured by standard methods on a Roche modular system (Roche) using blood tests taken at study visits. Estimated GFR (eGFR) was calculated using the 4-variable equation derived from the Modification of Diet in Renal Disease Study. 14 uPCR was measured on a random urine sample obtained during the clinic visit. A mean result for hemoglobin, adjusted calcium, phosphate, and albumin was calculated using all of the measurements taken for each participant at Brighton and Sussex University Hospitals National Health Service Trust over the 6 months preceding the study visit.
Intact parathyroid hormone was measured using the Elecsys sandwich electrochemiluminescence immunoassay method. This has no cross-reactivity to the 1 to 37 parathyroid hormone fragment.
Decline in Renal Function
Renal function was assessed using all of the measurements of serum creatinine available for each participant at Brighton and Sussex University Hospitals National Health Service Trust over the 5 years preceding closure of the database on July 1, 2008.
Decline in renal function was considered in 2 predefined ways. The first was through analysis of a gradient of reciprocal creatinine plots. Renal function data were censored at the start of renal replacement therapy, during temporary dialysis preceding study entry, or after limb amputation.
Second, a dichotomous combined end point of commencement of dialysis (excluding temporary dialysis) or Ն25% decline in Modification of Diet in Renal Disease eGFR since study entry was used. Details of dates of commencement of dialysis were taken from the patients' notes. Follow-up data were censored at the start of renal replacement therapy or death.
Cause of Renal Impairment
The cause of renal failure was assessed using a review of clinical history and investigations. Patients were classified as "hypertensive/ glomerulosclerosis" if patients had no clear evidence of active renal disease but a history of CV disease or several CV risk factors.
Statistical Analysis
Statistical analysis was carried out using SPSS version 15 (SPSS). Data were analyzed using appropriate tests after examination of distribution and skew. Comparisons between means of continuous variables were performed using the Student t test and Mann-Whitney U test as appropriate and between groups of dichotomous variables using the 2 test. All of the continuous data are presented as meanϮSD.
Aortic PWV is in part BP dependent, 15 so values were, therefore, adjusted for MBP at the time of measurement before further analysis. Adjustment was performed by a linear regression of the 2 variables. The residual values were then added to the mean aortic PWV. Values relate to adjusted measurements unless otherwise stated.
Because of obligatory covariance between variables, multivariate analysis was performed using a stepwise method with the same predefined parameters for both renal end-point and reciprocal creatinine plots. These were MBP adjusted aortic PWV, systolic BP, uPCR, diabetes mellitus, smoking history, and sex. Parameters for the multivariate model were selected if there was a previously recognized association or significant linear correlation. Variables rejected by the stepwise model are listed in Table 6 .
Results
Results are analyzed from 133 patients who entered the study. A total of 125 patients were white, and 8 were of Asian or Middle Eastern descent. The primary cause of renal failure is summarized in Table 1 . Mean duration of monitoring of renal function before incident recording of aortic PWV was 319 days (range: 0 to 867 days). Mean duration of follow-up after incident recording of aortic PWV was 551 days (range: 180 to 839 days). Baseline characteristics for the whole population are shown in Table 2 and medication use of the cohort at baseline in Table 3 .
Measurements of aortic PWV were obtained for 120 participants (90.2%). Thirteen were unavailable because of 
Reciprocal Creatinine Plot Analysis
Linear regression coefficients of univariate analyses of slope of reciprocal creatinine plot for all of the participants are shown in Table 4 . This analysis suggests that more rapid decline of renal function is associated with lower baseline eGFR, elevated uPCR, and higher aortic PWV. In addition, the mean slope of reciprocal creatinine plot was greater in diabetic patients, indicating more rapid decline in renal function in this group (Ϫ1.0ϫ10
Renal End Point Analysis
Comparison of characteristics of participants who did and did not reach the combined end point of commencement of dialysis or Ն25% decline in renal function is shown in Table  5 . Consistent with the results of the reciprocal creatinine plot analysis, there was a significant difference in uPCR and baseline eGFR between the group reaching the renal end point and those who did not progress. In addition, there were significant intergroup differences in BMI and intact parathyroid hormone. Aortic PWV was of borderline significance in this analysis.
There was no significant difference in the incidence of diabetes mellitus or the total number of antihypertensives used between groups. There was also no significant difference between the frequency of use of any class of antihypertensive or the use of statins, phosphate binders, or erythropoietin (data not shown).
Multivariate Analysis
The results of stepwise multivariate analysis for both outcome measures are shown in Table 6 . This demonstrates the significant independent association of aortic PWV with rate of change in renal function using both reciprocal creatinine plot and the renal end point models. SBP and uPCR were also retained in multivariate analysis of the renal end point model.
Variables not included in the final model are listed in Table 6 . Because PP is closely related to aortic stiffness, and PP has been shown previously to be a determinant of decline of renal function, 6, 16, 17 in addition to these predefined variables, the models were tested replacing SBP with PP. No independent relationship was found between PP and rate of renal decline using either model.
Discussion
Principal Findings
These results demonstrate for the first time that aortic stiffness is independently associated with the rate of decline of renal function in patients with CKD stages 3 and 4. Aortic stiffness, after adjustment for MBP, was independently associated with slope of reciprocal creatinine plot and with reaching a combined end point of commencing dialysis or Ն25% decline in eGFR. Other factors retained in this model, SBP and uPCR, are both well recognized in the etiology of renal disease progression. 18, 19 Implications A number of studies among patients with CKD have shown an independent cross-sectional relationship between aortic PWV and renal function, as assessed by equation-based or radioisotopic measurements. 3, 20, 21 However, the direction of causality is unclear. A longitudinal study of hypertensive patients showed elevated creatinine at baseline to be an independent predictor of progression of aortic stiffening after 6 years of follow-up. 22 A number of mechanisms have been identified in humans with CKD by which renal impairment may impact on arterial function, including impaired endothelial function, 23 oxidative stress, 24 inflammation, 25 and activation of the renin-angiotensin system. 26 In addition, arteriosclerosis may be affected by alteration of factors controlling arterial calcification, such as fetuin-A and osteoprotegerin, 27 whereas parathyroid hormone levels may have a direct effect on vascular tone. 28 Finally, a direct effect of uremia on arterial stiffness is supported by evidence suggesting that vascular compliance improves after successful renal transplantation. 29 Conversely, there is evidence to suggest that aortic stiffness plays a direct role in the deterioration of renal function. Two small studies have shown that measures of arterial stiffness, augmentation index and radial-dorsalis pedis PWV, were independent risk factors for the progression of renal disease in patients with CKD. 30, 31 A prospective longitudinal study did not find an association between aortic PWV and incident CKD, although it may have been underpowered to detect this in the healthy general population. 32 Increased aortic stiffness could promote deterioration of renal function through increased PP. This occurs because of alteration of the viscoelastic properties of the vessel wall and through changes in wave reflection resulting in augmentation of systolic pressure and loss of augmentation of diastolic pressure. 33 PP has been independently associated with decline of renal function in hypertensive patients 6, 16 and patients with established CKD. 17 The renal circulation is unique with respect to transmitted BP fluctuations. Although the microcirculation of other organs is protected by the high resistance of the precapillary arterioles, the renal afferent arterioles provide relatively low resistance. This permits transmission of hydrostatic pressure to the glomerular filtration barrier, producing a high glomerular filtration fraction. This renders the glomerulus susceptible to pressure related damage if the PP is elevated. 34 Ex vivo studies have demonstrated that acutely elevated pressure pulsatility leads to increased afferent arteriolar tone with associated reduction in the filtration fraction. 35 Compensatory changes occur via tubuloglomerular feedback with reninangiotensin-aldosterone system activation resulting in efferent arteriolar vasoconstriction to maintain glomerular filtration. More chronically in the hypertensive patient, loss of effective renal autoregulation is thought to manifest through afferent arteriolar dilatation with glomerular hypertrophy, hyperfiltration injury, and subsequent excess extracellular matrix production and glomerulosclerosis with irreversible reduction in GFR. 36, 37 In addition, reduced aortic compliance may contribute directly to renal injury, because loss of the dampening effect of ventricular ejection may result in increased transmission of central BP fluctuations to the renal vascular bed.
Selection of potential variables in the construction of a model of the CV determinants of renal disease progression is complicated by their inherent colinearity. MBP is an important determinant of PWV via distending pressure, and for this reason adjustment of PWV for MBP was made before entering aortic PWV into the model. Even if a model is constructed by entering unadjusted PWV and MBP using our data, no meaningful difference is made to the result.
SBP was included because it is widely regarded to be associated with renal function in both cross-sectional and longitudinal analyses via mechanisms including barotrauma.
The lack of independent association between PP and change in renal function in this population may be explained by the characteristics of the cohort. Although aortic stiffness is, as expected, correlated with PP, this relationship is weakened by ageing and concomitant CV comorbidity, including left ventricular impairment. 15, 38 There is a high proportion of older patients who have renal impairment because of hypertension or glomerulosclerosis and who have had previous CV disease within this study. Among patients such as these, there may be a significant incidence of undetected left ventricular impairment resulting in a reduction of the strength of the relationship between PP and aortic PWV. This may explain why, despite the association of aortic PWV with PP, aortic PWV is significantly associated with the end point and PP is not. However, a "vicious circle" of BP and aortic stiffening driving ongoing renal dysfunction could be proposed within these patients. Retention of SBP in this model is likely to reflect the pathological effect of high peak pressures in contrast to high pressure fluctuations reflected by PP or PWV.
Potential Limitations
This is an observational study of a limited number of patients with a wide range of age and renal diagnoses. The observational nature of the study means that the finding of an independent statistical association is not synonymous with that of the pathophysiological determinant.
The use of creatinine measurements from the period both before and after study entry in the calculation of the reciprocal creatinine plots limits determination of the direction of causality. These data were included to give a more accurate representation of the rate of renal function decline over time. However, this is not the case for the second predefined end point, which is based entirely on outcome subsequent to the measurement of aortic PWV.
Finally, calculation of aortic PWV was performed using the measured distance from carotid pulse to femoral pulse. This method differs from some other groups who use the distance obtained by subtraction of the carotid-sternum distance from the sternum-femoral distance. This methodological difference results in higher aortic PWV values in this study in comparison with other studies but does not affect subsequent data interpretation.
Perspectives
This study found that aortic stiffness is independently associated with progressive renal impairment in patients with CKD stages 3 and 4. The impact of aortic stiffening remained significant after inclusion of factors shown previously to be associated with renal function decline, including BP. While recognizing likely dual causality between aortic stiffness and renal dysfunction, these results strengthen the evidence that arterial stiffness plays an etiologic role in renal function decline. Aortic stiffness should be a target of future intervention studies to inhibit the progression of CKD.
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